Centers for Disease Control and Prevention Centers for Disease Control and Prevention CDC Home Search CDC CDC Health Topics A-Z site search
National Office of Public Health Genomics
Centers for Disease Control and Prevention
Office of Genomics and Disease Prevention
Site Search
 

Louise Wideroff Biographical Sketch

NAME
Louise Wideroff

POSITION TITLE
Program Director

eRA COMMONS USER NAME

EDUCATION/TRAINING 

INSTITUTION AND LOCATION

DEGREE

YEAR(s)

FIELD OF STUDY

National Cancer Institute

Postdoctoral Fellowship

1997

Cancer Epidemiology

University of Michigan

Ph.D.

1993

Epidemiology

University of Illinois

M.S.P.H.

1987

Epidemiology

Antioch University

B.A.

1979

Foreign Languages

  • Current Position

Program Director
National Cancer Institute, Division of Cancer Control and Population Sciences, Applied Research Program, Risk Factor Monitoring and Methods Branch, Rockville, MD (1997-current).

  • Training

Dr. Wideroff received her PhD in epidemiology from the University of Michigan. Prior to joining the Applied Research Program in 1997, she completed a post-doctoral fellowship in cancer epidemiology in the Division of Cancer Epidemiology and Genetics at NCI.

  • Expertise and Interests

She is currently is a program director and project officer in the Risk Factors Monitoring and Methods Branch of the Applied Research Program at NCI. Her areas of expertise include assessment and use of family history of cancer information, and clinical utility of emerging cellular, molecular, and genomic technologies in cancer prevention and control. She currently serves as program director for the Program Announcement entitled Understanding the Effects of Emerging Cellular, Molecular, and Genomic Technologies in Cancer Care. She has also served as NCI Project Officer on research contracts addressing family history of cancer accuracy and interpretability, physician use of genetic tests for inherited breast/ovarian and colorectal cancer susceptibility, and cancer risk associated with blood transfusions.

Her interests include molecular and modifiable risk factors for cancer progression, and effectiveness of and access to molecular diagnostic tools and targeted therapies in routine clinical care.

Page last updated: December 11, 2007
Content Source: National Office of Public Health Genomics